Suppr超能文献

美国医用大麻的使用:一项回顾性数据库研究。

Medical cannabis use in the United States: a retrospective database study.

作者信息

Mahabir V Kishan, Merchant Jamil J, Smith Christopher, Garibaldi Alisha

机构信息

CB2 Insights, 5045 Orbitor Dr, Building 11, Suite 300, Mississauga, ON, L4W 4Y4, Canada.

出版信息

J Cannabis Res. 2020 Sep 29;2(1):32. doi: 10.1186/s42238-020-00038-w.

Abstract

INTRODUCTION

Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a paucity of data characterizing the patients accessing medical cannabis programs.

METHODS

We retrospectively reviewed a registry with data from 33 medical cannabis evaluation clinics in the United States, owned and operated by CB2 Insights. Data were collected primarily by face-to-face interviews for patients seeking medical cannabis certification between November 18, 2018 and March 18, 2020. Patients were removed from the analysis if they did not have a valid date of birth, were less than 18, or did not have a primary medical condition reported; a total of 61,379 patients were included in the analysis. Data were summarized using descriptive statistics expressed as a mean (standard deviation (SD)) or median (interquartile range (IQR)) as appropriate for continuous variables, and number (percent) for categorical variables. Statistical tests performed across groups included t-tests, chi-squared tests and regression.

RESULTS

The average age of patients was 45.5, 54.8% were male and the majority were Caucasian (87.5%). Female patients were significantly older than males (47.0 compared to 44.6). Most patients reported cannabis experience prior to seeking medical certification (66.9%). The top three mutually exclusive primary medical conditions reported were unspecified chronic pain (38.8%), anxiety (13.5%) and post-traumatic stress disorder (PTSD) (8.4%). The average number of comorbid conditions reported was 2.7, of which anxiety was the most common (28.3%). Females reported significantly more comorbid conditions than males (3.1 compared to 2.3).

CONCLUSION

This retrospective study highlighted the range and number of conditions for which patients in the US seek medical cannabis. Rigorous clinical trials investigating the use of medical cannabis to treat pain conditions, anxiety, insomnia, depression and PTSD would benefit a large number of patients, many of whom use medical cannabis to treat multiple conditions.

摘要

引言

人们对大麻药用特性的兴趣日益浓厚,这导致其在治疗疾病方面的使用有所增加,并且各地也纷纷建立了特定州的医用大麻项目。尽管医用大麻在33个州和哥伦比亚特区是合法的,但关于使用医用大麻项目的患者特征的数据仍然匮乏。

方法

我们回顾性地审查了由CB2 Insights拥有和运营的美国33家医用大麻评估诊所的数据登记册。数据主要通过对2018年11月18日至2020年3月18日期间寻求医用大麻认证的患者进行面对面访谈收集。如果患者没有有效的出生日期、年龄小于18岁或未报告主要疾病,则将其从分析中排除;共有61379名患者纳入分析。数据使用描述性统计进行总结,连续变量根据情况表示为均值(标准差(SD))或中位数(四分位间距(IQR)),分类变量表示为数量(百分比)。各组间进行的统计检验包括t检验、卡方检验和回归分析。

结果

患者的平均年龄为45.5岁,54.8%为男性,大多数为白种人(87.5%)。女性患者明显比男性年龄大(分别为47.0岁和44.6岁)。大多数患者在寻求医用大麻认证之前就有使用大麻的经历(66.9%)。报告的前三种相互排斥的主要疾病是未明确的慢性疼痛(38.8%)、焦虑症(13.5%)和创伤后应激障碍(PTSD)(8.4%)。报告的合并症平均数量为2.7种,其中焦虑症最为常见(28.3%)。女性报告的合并症明显多于男性(分别为3.1种和2.3种)。

结论

这项回顾性研究突出了美国患者寻求医用大麻治疗的疾病范围和数量。对使用医用大麻治疗疼痛性疾病、焦虑症、失眠、抑郁症和创伤后应激障碍进行严格的临床试验将使大量患者受益,其中许多患者使用医用大麻来治疗多种疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20a8/7819290/ad56ec7daf4b/42238_2020_38_Fig1_HTML.jpg

相似文献

1
Medical cannabis use in the United States: a retrospective database study.
J Cannabis Res. 2020 Sep 29;2(1):32. doi: 10.1186/s42238-020-00038-w.
2
Comparing medical cannabis use in 5 US states: a retrospective database study.
J Cannabis Res. 2021 May 27;3(1):15. doi: 10.1186/s42238-021-00075-z.
4
Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects.
Drugs Aging. 2022 Feb;39(2):153-163. doi: 10.1007/s40266-021-00913-y. Epub 2021 Dec 23.
6
Understanding the Orthopedic Conditions for Which Patients Are Seeking Medical Cannabis Certification.
Cureus. 2024 Jan 23;16(1):e52829. doi: 10.7759/cureus.52829. eCollection 2024 Jan.
7
Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry.
Expert Rev Neurother. 2022 Nov-Dec;22(11-12):1009-1018. doi: 10.1080/14737175.2022.2155139. Epub 2022 Dec 12.
8
Medicinal cannabis: knowledge, beliefs, and attitudes of Colombian psychiatrists.
J Cannabis Res. 2021 Jul 5;3(1):26. doi: 10.1186/s42238-021-00083-z.
9
[Comorbidity in 207 cannabis users in a specific outpatient setting].
Encephale. 2015 Jun;41 Suppl 1:S7-12. doi: 10.1016/j.encep.2014.06.004. Epub 2014 Aug 12.
10
Mapping cannabis potency in medical and recreational programs in the United States.
PLoS One. 2020 Mar 26;15(3):e0230167. doi: 10.1371/journal.pone.0230167. eCollection 2020.

引用本文的文献

2
Relationship Between Cannabis Dispensary Density, Proximity, and Attitudes Toward Medical Cannabis: A Cross-Sectional Study.
Health Sci Rep. 2025 Apr 21;8(4):e70685. doi: 10.1002/hsr2.70685. eCollection 2025 Apr.
3
An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans.
Pharmaceutics. 2025 Mar 1;17(3):319. doi: 10.3390/pharmaceutics17030319.
5
Motherhood and medicinal cannabis.
Drug Alcohol Rev. 2025 May;44(4):1024-1035. doi: 10.1111/dar.14027. Epub 2025 Feb 18.
6
The association between cannabis and depression: an updated Systematic Review and Meta-analysis.
Psychol Med. 2025 Feb 12;55:e44. doi: 10.1017/S0033291724003143.
8
Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials.
Child Adolesc Psychiatry Ment Health. 2024 Dec 18;18(1):158. doi: 10.1186/s13034-024-00846-5.
9
Use of Cannabis-Based Medical Products for Pediatric Health Conditions: A Systematic Review of the Recent Literature.
Med Cannabis Cannabinoids. 2024 Dec 10;7(1):257-267. doi: 10.1159/000542550. eCollection 2024 Jan-Dec.
10
Increased active pulmonary tuberculosis risk from sharing bong of cannabis: a case-control study from Thailand.
Front Public Health. 2024 Nov 13;12:1474761. doi: 10.3389/fpubh.2024.1474761. eCollection 2024.

本文引用的文献

3
Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis.
Soc Sci Med. 2019 Jul;233:181-192. doi: 10.1016/j.socscimed.2019.06.005. Epub 2019 Jun 8.
5
Population-wide analysis of differences in disease progression patterns in men and women.
Nat Commun. 2019 Feb 8;10(1):666. doi: 10.1038/s41467-019-08475-9.
6
Qualifying Conditions Of Medical Cannabis License Holders In The United States.
Health Aff (Millwood). 2019 Feb;38(2):295-302. doi: 10.1377/hlthaff.2018.05266.
7
Medicinal Cannabis-Potential Drug Interactions.
Medicines (Basel). 2018 Dec 23;6(1):3. doi: 10.3390/medicines6010003.
8
Cannabinoids and Pain: New Insights From Old Molecules.
Front Pharmacol. 2018 Nov 13;9:1259. doi: 10.3389/fphar.2018.01259. eCollection 2018.
9
Medical Use of Cannabinoids.
Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1.
10
A Brief Background on Cannabis: From Plant to Medical Indications.
J AOAC Int. 2019 Mar 1;102(2):412-420. doi: 10.5740/jaoacint.18-0208. Epub 2018 Aug 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验